How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,722 results for

macrolides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Does long-term treatment with macrolide antibiotics reduce asthma exacerbations in adults with eosinophilic and/or non-eosinophilic asthma?

Does long-term treatment with macrolide antibiotics reduce asthma exacerbations in adults with eosinophilic and/or non-eosinophilic asthma? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

182. Macrolide Antibiotics Exhibit Cytotoxic Effect under Amino Acid-Depleted Culture Condition by Blocking Autophagy Flux in Head and Neck Squamous Cell Carcinoma Cell Lines. Full Text available with Trip Pro

Macrolide Antibiotics Exhibit Cytotoxic Effect under Amino Acid-Depleted Culture Condition by Blocking Autophagy Flux in Head and Neck Squamous Cell Carcinoma Cell Lines. Autophagy, a self-digestive system for cytoplasmic components, is required to maintain the amino acid pool for cellular homeostasis. We previously reported that the macrolide antibiotics azithromycin (AZM) and clarithromycin (CAM) have an inhibitory effect on autophagy flux, and they potently enhance the cytocidal effect (...) of various anticancer reagents in vitro. This suggests that macrolide antibiotics can be used as an adjuvant for cancer chemotherapy. Since cancer cells require a larger metabolic demand than normal cells because of their exuberant growth, upregulated autophagy in tumor cells has now become the target for cancer therapy. In the present study, we examined whether macrolides exhibit cytotoxic effect under an amino acid-starving condition in head and neck squamous cancer cell lines such as CAL 27

2016 PLoS ONE

183. Use of macrolides and risk of fetal malformations

Use of macrolides and risk of fetal malformations Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect

2017 PROSPERO

184. The cardiovascular safety of macrolides: a systematic review, meta-analysis and network meta-analysis

The cardiovascular safety of macrolides: a systematic review, meta-analysis and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2017 PROSPERO

185. Macrolides for treatment of neutrophil-dominated airway diseases in adults: a meta-analysis on effectiveness and safety

Macrolides for treatment of neutrophil-dominated airway diseases in adults: a meta-analysis on effectiveness and safety Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

186. Macrolides for treatment of Haemophilus ducreyi infection in sexually-active adults [Cochrane protocol]

Macrolides for treatment of Haemophilus ducreyi infection in sexually-active adults [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2017 PROSPERO

187. Macrolide antibiotics for non-cystic fibrosis bronchiectasis [Cochrane protocol]

Macrolide antibiotics for non-cystic fibrosis bronchiectasis [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2017 PROSPERO

188. Macrolide antibiotics for non-cystic fibrosis bronchiectasis [Cochrane Protocol]

Macrolide antibiotics for non-cystic fibrosis bronchiectasis [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2017 PROSPERO

189. Macrolides for diffuse panbronchiolitis. (Abstract)

Macrolides for diffuse panbronchiolitis. Diffuse panbronchiolitis (DPB) is a chronic airways disease predominantly affecting East Asians. Macrolides, a class of antibiotics, have been used as the main treatment for DPB, based on evidence from retrospective and non-randomised studies.To assess the efficacy and safety of macrolides for DPB.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, issue 1), which contains the Cochrane Acute Respiratory (...) Infections Group's Specialised Register, MEDLINE (1966 to April 2010), EMBASE (1974 to April 2010), Chinese Biomedical Literature Database (CBM) (1978 to April 2010), China National Knowledge Infrastructure (CNKI) (1974 to April 2010), KoreaMed (1997 to April 2010) and Database of Japana Centra Revuo Medicina (1983 to April 2010).Randomised controlled trials (RCTs) or quasi-RCTs assessing the effect of macrolides for DPB.Two review authors independently assessed study quality and subsequent risk of bias

2010 Cochrane

190. A highly macrolide-resistant Campylobacter jejuni strain with rare A2074T mutations in 23S rRNA genes. Full Text available with Trip Pro

A highly macrolide-resistant Campylobacter jejuni strain with rare A2074T mutations in 23S rRNA genes. 26810658 2016 12 13 2018 11 13 1098-6596 60 4 2016 Apr Antimicrobial agents and chemotherapy Antimicrob. Agents Chemother. A Highly Macrolide-Resistant Campylobacter jejuni Strain with Rare A2074T Mutations in 23S rRNA Genes. 2580-1 10.1128/AAC.02822-15 Ohno Hiroe H Department of Bacteriology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. Wachino Jun-Ichi J Department (...) , Japan. Kimura Kouji K Department of Bacteriology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. Arakawa Yoshichika Y Department of Bacteriology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. eng Letter Research Support, Non-U.S. Gov't 2016 03 25 United States Antimicrob Agents Chemother 0315061 0066-4804 0 Anti-Bacterial Agents 0 Macrolides 0 RNA, Ribosomal, 23S IM Anti-Bacterial Agents pharmacology Campylobacter Infections drug therapy microbiology

2016 Antimicrobial Agents and Chemotherapy

191. Macrolides and associated antibiotics based on similar mechanism of action like lincosamides in malaria. Full Text available with Trip Pro

Macrolides and associated antibiotics based on similar mechanism of action like lincosamides in malaria. Malaria, a parasite vector-borne disease, is one of the biggest health threats in tropical regions, despite the availability of malaria chemoprophylaxis. The emergence and rapid extension of Plasmodium falciparum resistance to various anti-malarial drugs has gradually limited the potential malaria therapeutics available to clinicians. In this context, macrolides and associated antibiotics (...) with quinine. This literature review assesses the roles of macrolides and lincosamides in the prophylaxis and treatment of malaria.

2016 Malaria journal

192. Increased clinical failures when treating acute otitis media with macrolides: a meta-analysis

Increased clinical failures when treating acute otitis media with macrolides: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

193. Macrolide and Clindamycin Resistance in Group A Streptococci Isolated from Children With Pharyngitis. (Abstract)

Macrolide and Clindamycin Resistance in Group A Streptococci Isolated from Children With Pharyngitis. Group A streptococcus (GAS) is responsible for 15%-30% of cases of acute pharyngitis in children. Macrolides such as azithromycin have become popular for treating GAS pharyngitis. We report macrolide resistance rates in a primary care setting in our geographic area over the past 5 years and discuss the implications of resistance in making treatment decisions. Throat swabs were collected from

2016 Pediatric Infectious Dsease Journal

194. Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. Full Text available with Trip Pro

Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. The best treatment option for hospitalized patients with community-acquired pneumonia (CAP) has not been defined. The effectiveness of β-lactam/fluoroquinolone (BLFQ) versus β-lactam/macrolide (BLM) combinations for the treatment of patients with CAP was evaluated.PubMed, Scopus and the Cochrane Library were searched (...) for observational cohort studies, non-randomized and randomized controlled trials providing data for patients with CAP receiving BLM or BLFQ. Mortality was the primary outcome. A meta-analysis was performed. MINORS and GRADE were used for data quality assessment.Seventeen studies (16 684 patients) were included. Randomized trials were not identified. A variety of β-lactams, fluoroquinolones and macrolides were used within and between the studies. Mortality was reported at different time points. The available

2016 Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

195. Antibiotics in malaria therapy: which antibiotics except tetracyclines and macrolides may be used against malaria? Full Text available with Trip Pro

Antibiotics in malaria therapy: which antibiotics except tetracyclines and macrolides may be used against malaria? Malaria, a parasite vector-borne disease, is one of the most significant health threats in tropical regions, despite the availability of individual chemoprophylaxis. Malaria chemoprophylaxis and chemotherapy remain a major area of research, and new drug molecules are constantly being developed before drug-resistant parasites strains emerge. The use of anti-malarial drugs (...) is challenged by contra-indications, the level of resistance of Plasmodium falciparum in endemic areas, clinical tolerance and financial cost. New therapeutic approaches are currently needed to fight against this disease. Some antibiotics that have shown potential effects on malaria parasite have been recently studied in vitro or in vivo intensively. Two families, tetracyclines and macrolides and their derivatives have been particularly studied in recent years. However, other less well-known have been

2016 Malaria journal

196. Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-resistant Mycobacterium massiliense Lung Disease. Full Text available with Trip Pro

Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-resistant Mycobacterium massiliense Lung Disease. Macrolide antibiotics are cornerstones in the treatment of Mycobacterium massiliense lung disease. Despite the emergence of resistance, limited data on macrolide-resistant M massiliense lung disease are available. This study evaluated the clinical features and treatment outcomes of patients and the molecular characteristics of macrolide-resistant M massiliense isolates (...) . We performed a retrospective review of medical records and genetic analyses of clinical isolates from 15 patients who had macrolide-resistant M massiliense lung disease between September 2005 and February 2015. Nine patients (60%) had the nodular bronchiectatic form of the disease, and six (40%) had the fibrocavitary form. Before the detection of macrolide resistance, three patients (20%) were treated with macrolide monotherapy, four (27%) with therapy for presumed Mycobacterium avium complex

2016 Antimicrobial Agents and Chemotherapy

197. Solithromycin, a novel macrolide, does not prolong cardiac repolarization: a randomized, three-way crossover study in healthy subjects. Full Text available with Trip Pro

Solithromycin, a novel macrolide, does not prolong cardiac repolarization: a randomized, three-way crossover study in healthy subjects. Macrolide antibiotics may cause QT prolongation.To study the QT effect of a novel macrolide, solithromycin.This was a thorough QT study with a three-way crossover design performed in healthy male and female subjects to evaluate the ECG effects of a novel macrolide, solithromycin. Forty-eight subjects were randomized to receive 800 mg of intravenous (iv (...) response. Solithromycin did not have a clinically meaningful effect on the PR or QRS interval.The study demonstrated that solithromycin, unlike other macrolide antibiotics, does not cause QT prolongation.© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

2016 Journal of Antimicrobial Chemotherapy Controlled trial quality: uncertain

198. Long-term efficacy of macrolide treatment in idiopathic pulmonary fibrosis: a retrospective analysis. (Abstract)

Long-term efficacy of macrolide treatment in idiopathic pulmonary fibrosis: a retrospective analysis. There is growing evidence for anti-inflammatory activities of macrolides in chronic respiratory diseases, such as diffuse panbronchiolitis, cystic fibrosis, or chronic bronchitis. The long-term effect of macrolides in idiopathic pulmonary fibrosis (IPF) is unknown. This study was aimed to investigate the effect of macrolide therapy on the frequency of acute exacerbation (AE) and the mortality (...) in IPF.A total 52 IPF patients who were treated by combination of conventional agents with or without macrolides were retrospectively reviewed. The primary endpoint was the incidence of AE in IPF patients. We also observed survival rate after the treatment with or without macrolides.AE was observed in 4 of 29 cases (13.8%) treated with macrolides and 8 of 23 cases (34.8%) treated without macrolides, respectively during 36 months. AE free survival rate of macrolide group was significantly better than

2016 Sarcoidosis, Vasculitis, and Diffuse Lung Diseases

199. A novel erm(44) gene variant from a human Staphylococcus saprophyticus confers resistance to macrolides, lincosamides but not streptogramins. Full Text available with Trip Pro

A novel erm(44) gene variant from a human Staphylococcus saprophyticus confers resistance to macrolides, lincosamides but not streptogramins. A novel erm(44) gene variant, erm(44)v, has been identified by whole-genome sequencing in a Staphylococcus saprophyticus isolate from the skin of a healthy person. It has the particularity to confer resistance to macrolides and lincosamides but not to streptogramin B when expressed in S. aureus The erm(44)v gene resides on a 19,400-bp genomic island which

2016 Antimicrobial Agents and Chemotherapy

200. Respiratory drugs and macrolides prevent asthma exacerbations: A real-world investigation. Full Text available with Trip Pro

Respiratory drugs and macrolides prevent asthma exacerbations: A real-world investigation. We investigated the real-world effectiveness of several drugs (including short- and long-acting beta-agonists [SABAs and LABAs], inhaled corticosteroids [ICS], and antibiotics) in preventing severe asthma exacerbations by carrying-out a large observational study based on the healthcare utilization databases of the Italian Lombardy Region.We identified all patients aged 6-40 years who performed (...) , 0.79 (0.65, 0.97) for other respiratory drugs, and 0.79 (0.69, 0.92) for macrolides antibiotics. Sensitivity analyses showed that our results were robust with respect to several sources of bias.Our study provides evidence from the real-world clinical practice on the effectiveness of several respiratory drugs and macrolides in reducing the risk of severe asthma exacerbations.Copyright © 2016. Published by Elsevier Ltd.

2016 Respiratory medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>